» Articles » PMID: 16819511

STAT5 Represses BCL6 Expression by Binding to a Regulatory Region Frequently Mutated in Lymphomas

Overview
Journal Oncogene
Date 2006 Jul 5
PMID 16819511
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Deregulated expression of BCL6 is a pathogenic event in many lymphomas. BCL6 blocks cellular differentiation by repressing transcription of its target genes, and this may promote tumorigenesis. Conversely, the transcription factor signal transducers and activators of transcription (STAT)5 promotes differentiation in many systems. STAT5 upregulates a number of genes repressed by BCL6, raising the possibility that STAT5 and BCL6 have opposing roles in transcriptional regulation. Therefore, we sought to determine the effects of STAT5 activation on BCL6 expression and function. We found that activation of STAT5 downregulates BCL6 expression in B-lymphoma cells and other hematopoietic cell lines. We identified two potential STAT-binding regions in the first exon and first intron of BCL6 that fell within regions of high inter-species homology, suggesting conservation of regulatory function. STAT5 can bind inducibly and regulate transcription at one of these regions, identifying BCL6 as a STAT5 target gene. Additionally, STAT5-mediated downregulation of BCL6 results in loss of BCL6 repression of its target genes, confirming that STAT5 is a negative regulator of BCL6 function. The STAT5 responsive region of the BCL6 gene is mutated frequently in B-cell lymphomas, suggesting that loss of the repressive effects of STAT5 on BCL6 might contribute to the pathogenesis of these cancers.

Citing Articles

B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and Beyond.

Liongue C, Almohaisen F, Ward A Int J Mol Sci. 2024; 25(20).

PMID: 39456751 PMC: 11507070. DOI: 10.3390/ijms252010968.


Signal Transducer and Activator of Transcription Proteins at the Nexus of Immunodeficiency, Autoimmunity and Cancer.

Liongue C, Sobah M, Ward A Biomedicines. 2024; 12(1).

PMID: 38255152 PMC: 10813391. DOI: 10.3390/biomedicines12010045.


BTB protein family and human breast cancer: signaling pathways and clinical progress.

Zhang H, Ouyang C J Cancer Res Clin Oncol. 2023; 149(17):16213-16229.

PMID: 37682360 DOI: 10.1007/s00432-023-05314-9.


BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.

Li K, Liu Y, Ding Y, Zhang Z, Feng J, Hu J J Clin Invest. 2022; 132(22).

PMID: 36377663 PMC: 9663163. DOI: 10.1172/JCI161308.


B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.

McLachlan T, Matthews W, Jackson E, Staudt D, Douglas A, Findlay I Mol Cancer Res. 2022; 20(12):1711-1723.

PMID: 36166198 PMC: 9716245. DOI: 10.1158/1541-7786.MCR-22-0567.